Skip to main navigation

About Us
- Leadership
- Board of Directors
Science
- Our Approach
- About CNM-Au8®
Pipeline
EAP
- EAP
- ACT-EAP WITH CNM-Au8®
Investors
Contact

About Us
- Leadership
- Board of Directors
Science
- Our Approach
- About CNM-Au8®
Pipeline
EAP
- EAP
- ACT-EAP WITH CNM-Au8®
Investors
Contact

Webinars

CNM-Au8 ALS Program Update

Dec 3, 2025 at 8:30 AM EST

Listen to webcast

Supporting Materials

View Presentation 5.9 MB

View Transcript 232 KB

Clene Inc. Presentation of CNM-Au8 Topline Data From the HEALEY ALS Platform Trial

Oct 3, 2022

Clene Inc. – Phase 2 VISIONARY-MS Trial Results

Aug 15, 2022

Clene Inc. Presentation of RESCUE-ALS Topline Clinical Trial Results

Nov 2, 2021

Supporting Materials

Presentation 23.4 MB

Expert Perspectives Webinar - Cellular Energetic Failure: Addressing Unmet Needs and a New Investigational Treatment for ALS and MS

Jul 14, 2021

Supporting Materials

Clene Expert Perspectives 423.8 KB

1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2026 Clene Nanomedicine, Inc. - All rights reserved | PRIVACY POLICY | COOKIE POLICY | TERMS OF USE